You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Cardiac MRI as end point in clinical trials
  1. Ingo Eitel,
  2. Steffen Desch,
  3. Holger Thiele
  1. Department of Internal Medicine/Cardiology, University of Leipzig—Heart Center, Leipzig, Germany
  1. Correspondence to Dr Ingo Eitel, Department of Internal Medicine/Cardiology, University of Leipzig—Heart Center, Strümpellstr. 39, 04289 Leipzig, Germany; ingoeitel{at}gmx.de

https://doi.org/10.1136/heartjnl-2011-300847

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    To the Editor We read with great interest the recent review article by Alex Pitcher and coworkers highlighting the role of cardiac MRI as a surrogate end point in clinical trials.1 The authors focus on vascular imaging, measurement of infarct size by late gadolinium enhancement (LGE) and measurement of ventricular volumes, …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles

    • PostScript
      The Authors' reply
      Alex Pitcher Deborah Ashby Paul Elliott Steffen E Petersen
      Heart 2011; 97 1991-1991 Published Online First: 11 Oct 2011. doi: 10.1136/heartjnl-2011-301002